Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.

Bibby BA, Reynolds JV, Maher SG.

PLoS One. 2015 Jul 29;10(7):e0134180. doi: 10.1371/journal.pone.0134180. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0137155.

2.

Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.

Lynam-Lennon N, Bibby BA, Mongan AM, Marignol L, Paxton CN, Geiersbach K, Bronner MP, O'Sullivan J, Reynolds J, Maher SG.

Mol Med. 2016 May 23;22. doi: 10.2119/molmed.2016.00020.

3.

MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype.

Lynam-Lennon N, Heavey S, Sommerville G, Bibby BA, Ffrench B, Quinn J, Gasch C, O'Leary JJ, Gallagher MF, Reynolds JV, Maher SG.

Oncotarget. 2017 Feb 14;8(7):11400-11413. doi: 10.18632/oncotarget.13940.

4.

Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Yu J, Li N, Wang X, Ren H, Wang W, Wang S, Song Y, Liu Y, Li Y, Zhou X, Luo A, Liu Z, Jin J.

Oncotarget. 2016 Sep 27;7(39):64233-64243. doi: 10.18632/oncotarget.11649.

5.

MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.

Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O.

Radiat Oncol. 2012 Nov 20;7:195. doi: 10.1186/1748-717X-7-195.

6.

Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.

Lopes-Ramos CM, Habr-Gama A, Quevedo Bde S, Felício NM, Bettoni F, Koyama FC, Asprino PF, Galante PA, Gama-Rodrigues J, Camargo AA, Perez RO, Parmigiani RB.

BMC Med Genomics. 2014 Dec 11;7:68. doi: 10.1186/s12920-014-0068-7.

7.

MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma.

Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG.

J Mol Med (Berl). 2012 Dec;90(12):1449-58. doi: 10.1007/s00109-012-0924-x. Epub 2012 Jun 17.

PMID:
22706599
8.

MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.

Wen J, Luo K, Liu H, Liu S, Lin G, Hu Y, Zhang X, Wang G, Chen Y, Chen Z, Li Y, Lin T, Xie X, Liu M, Wang H, Yang H, Fu J.

Ann Surg. 2016 May;263(5):942-8. doi: 10.1097/SLA.0000000000001489.

PMID:
26445467
9.

Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.

Matsui D, Zaidi AH, Martin SA, Omstead AN, Kosovec JE, Huleihel L, Saldin LT, DiCarlo C, Silverman JF, Hoppo T, Finley GG, Badylak SF, Kelly RJ, Jobe BA.

Oncotarget. 2016 Dec 6;7(49):81281-81291. doi: 10.18632/oncotarget.12832. Review.

10.

Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.

Odenthal M, Hee J, Gockel I, Sisic L, Schmitz J, Stoecklein NH, Driemel C, Möhlendick B, Schmidt T, Knoefel WT, Lang H, Büttner R, Ott K, Vallböhmer D.

Int J Cancer. 2015 Jul 1;137(1):230-7. doi: 10.1002/ijc.29363. Epub 2014 Dec 3.

11.

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.

Bain GH, Collie-Duguid E, Murray GI, Gilbert FJ, Denison A, McKiddie F, Ahearn T, Fleming I, Leeds J, Phull P, Park K, Nanthakumaran S, Matula KM, Grabsch HI, Tan P, Welch A, Schweiger L, Dahle-Smith A, Urquhart G, Finegan M, Petty RD.

Br J Cancer. 2014 Mar 18;110(6):1525-34. doi: 10.1038/bjc.2014.45. Epub 2014 Feb 25. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1641. Matula, K M [added].

12.

YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.

Senetta R, Duregon E, Sonetto C, Spadi R, Mistrangelo M, Racca P, Chiusa L, Munoz FH, Ricardi U, Arezzo A, Cassenti A, Castellano I, Papotti M, Morino M, Risio M, Cassoni P.

PLoS One. 2015 Apr 15;10(4):e0123759. doi: 10.1371/journal.pone.0123759. eCollection 2015.

13.

Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma.

Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, Zhao Z, Xu Z, El-Rifai W.

Cancer. 2013 Jun 1;119(11):1985-93. doi: 10.1002/cncr.28002. Epub 2013 Mar 1.

14.

Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma.

Lynam-Lennon N, Maher SG, Maguire A, Phelan J, Muldoon C, Reynolds JV, O'Sullivan J.

PLoS One. 2014 Jun 26;9(6):e100738. doi: 10.1371/journal.pone.0100738. eCollection 2014.

15.

A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma.

Skinner HD, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, Ajani J, Wu X.

Cancer. 2014 Dec 1;120(23):3635-41. doi: 10.1002/cncr.28911. Epub 2014 Aug 4.

16.
17.

MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.

Hummel R, Sie C, Watson DI, Wang T, Ansar A, Michael MZ, Van der Hoek M, Haier J, Hussey DJ.

World J Gastroenterol. 2014 Oct 28;20(40):14904-12. doi: 10.3748/wjg.v20.i40.14904.

18.

Radiation sensitivity of esophageal adenocarcinoma: the contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance.

Hötte GJ, Linam-Lennon N, Reynolds JV, Maher SG.

Radiat Res. 2012 Mar;177(3):272-9. Epub 2012 Jan 3.

PMID:
22214381
19.

Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.

Winther M, Alsner J, Tramm T, Baeksgaard L, Holtved E, Nordsmark M.

Acta Oncol. 2015;54(9):1582-91. doi: 10.3109/0284186X.2015.1064161.

PMID:
26481465
20.

Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.

Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, Haier J, Hummel R.

J Exp Clin Cancer Res. 2014 Sep 1;33:73. doi: 10.1186/s13046-014-0073-x.

Supplemental Content

Support Center